You just read:

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

News provided by

ReportBuyer

12 Jan, 2017, 15:19 ET